JP2017536343A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536343A5
JP2017536343A5 JP2017518929A JP2017518929A JP2017536343A5 JP 2017536343 A5 JP2017536343 A5 JP 2017536343A5 JP 2017518929 A JP2017518929 A JP 2017518929A JP 2017518929 A JP2017518929 A JP 2017518929A JP 2017536343 A5 JP2017536343 A5 JP 2017536343A5
Authority
JP
Japan
Prior art keywords
amino
carboxy
butanoyl
ethoxy
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017518929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/073372 external-priority patent/WO2016055610A1/en
Publication of JP2017536343A publication Critical patent/JP2017536343A/ja
Publication of JP2017536343A5 publication Critical patent/JP2017536343A5/ja
Withdrawn legal-status Critical Current

Links

JP2017518929A 2014-10-10 2015-10-09 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト Withdrawn JP2017536343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188421 2014-10-10
EP14188421.3 2014-10-10
PCT/EP2015/073372 WO2016055610A1 (en) 2014-10-10 2015-10-09 Stable glp-1 based glp-1/glucagon receptor co-agonists

Publications (2)

Publication Number Publication Date
JP2017536343A JP2017536343A (ja) 2017-12-07
JP2017536343A5 true JP2017536343A5 (enExample) 2018-11-08

Family

ID=51663097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518929A Withdrawn JP2017536343A (ja) 2014-10-10 2015-10-09 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト

Country Status (7)

Country Link
US (1) US9988430B2 (enExample)
EP (1) EP3204408B1 (enExample)
JP (1) JP2017536343A (enExample)
CN (1) CN107108713A (enExample)
ES (1) ES2805326T3 (enExample)
TW (1) TW201629095A (enExample)
WO (1) WO2016055610A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
KR102608220B1 (ko) 2016-05-06 2023-11-29 아이오니스 파마수티컬즈, 인코포레이티드 Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
JP6601578B2 (ja) * 2017-07-13 2019-11-06 不二製油グループ本社株式会社 ペプチド
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US20090209469A1 (en) * 2006-08-04 2009-08-20 Dennis Kim Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN102075337A (zh) 2009-11-20 2011-05-25 腾讯科技(深圳)有限公司 一种即时通信消息显示方法和相关装置
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112012018104A2 (pt) 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
MA34383B1 (fr) * 2010-06-24 2013-07-03 Zealand Pharma As Analogues de glucagon
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013041678A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
BR112016016321A2 (pt) 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica

Similar Documents

Publication Publication Date Title
JP2017536343A5 (enExample)
JP2016526012A5 (enExample)
RU2015146600A (ru) Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
JP2012529463A5 (enExample)
RU2434019C2 (ru) Ацилированные glp-1 соединения
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
JP7095027B2 (ja) 新規のアミリン及びカルシトニン受容体アゴニスト
JP2016531156A5 (enExample)
JP2008533105A5 (enExample)
KR102302634B1 (ko) 변형된 치료제 및 이의 조성물
KR102455171B1 (ko) 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
JP2010538049A5 (enExample)
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
JP2018505146A5 (enExample)
JP2013533849A5 (enExample)
JP2012506402A5 (enExample)
CA2797089A1 (en) Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
JP2011524420A5 (enExample)
JP2016500682A5 (enExample)
JP2014527975A5 (enExample)
JP2013518115A5 (enExample)
JP2011502159A5 (enExample)
JP2012518035A5 (enExample)
JP2011526886A5 (enExample)
JP2013523618A5 (enExample)